Related Experiment Video
Updated: Jul 18, 2026

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability
Kuo-Long Yu1, Ny Sin, Rita L Civiello
1Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA.
Abstract:
A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes. 1-Cyclopropyl-1,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one (6m, BMS-433771) was identified as a potent RSV inhibitor demonstrating good bioavailability in the mouse, rat, dog and cynomolgus monkey that demonstrated antiviral activity in the BALB/c and cotton rat models of infection following oral administration.
More Related Videos
Related Concept Videos
Respiratory Syncytial Virus Disease
Modified-Release Drug Delivery Systems: Bioavailability
Bioavailability Enhancement: Drug Solubility Enhancement
IV Infusion to Oral Dosing: Conversion Methods
Bioavailability Enhancement: Drug Permeability Enhancement
Oral Drug Delivery Systems: Introduction

